Dual Inhibitors of P-gp and Carbonic Anhydrase XII (hCA XII) against Tumor Multidrug Resistance with Piperazine Scaffold.
A549/DOX
CA XII inhibitors
HT29/DOX
K562/DOX
MDR reversers
P-gp modulators
dual P-gp/CA XII inhibitory activity
hybrid compounds
multitarget ligands
selective chemosensitizers
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
received:
29
05
2024
revised:
08
07
2024
accepted:
09
07
2024
medline:
27
7
2024
pubmed:
27
7
2024
entrez:
27
7
2024
Statut:
epublish
Résumé
A new series of piperazine derivatives were synthesized and studied with the aim of obtaining dual inhibitors of P-glycoprotein (P-gp) and carbonic anhydrase XII (hCA XII) to synergistically overcome the P-gp-mediated multidrug resistance (MDR) in cancer cells expressing the two proteins, P-gp and hCA XII. Indeed, these hybrid compounds contain both P-gp and hCA XII binding groups on the two nitrogen atoms of the heterocyclic ring. All compounds showed good inhibitory activity on each protein (P-gp and hCA XII) studied individually, and many of them showed a synergistic effect in the resistant HT29/DOX and A549/DOX cell lines which overexpress both the target proteins. In particular, compound
Identifiants
pubmed: 39064868
pii: molecules29143290
doi: 10.3390/molecules29143290
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM